Key result
Tailored physical activity intervention proves feasible during lymphoma treatment, achieving ~85% adherence.
Why the study?
The feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention in lymphoma patients undergoing chemotherapy needed to be determined.
Does a 6-month tailored physical activity intervention improve feasibility, exercise capacity, and cardiovascular function in adults with lymphoma undergoing cardiotoxic treatment?
RCT (n=20)
Single-blind
Variably sized permuted block randomization
Yes
Does a 6-month tailored physical activity intervention improve feasibility, exercise capacity, and cardiovascular function in adults with lymphoma undergoing cardiotoxic treatment?
Absolute Event Rate: 85% vs 87.1%
A tailored physical activity intervention is feasible and safe for patients with lymphoma undergoing potentially cardiotoxic chemotherapy, showing preliminary potential to preserve exercise capacity.
Supports tailored activity programs in lymphoma chemotherapy; extends feasibility data to inform larger efficacy RCTs.
To determine the feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention (PAI) for lymphoma patients undergoing chemotherapy. Patients newly diagnosed with lymphoma (non-Hodgkin (NHL) or Hodgkin (HL)) were randomized into the PAI or healthy living intervention (HLI) control (2:1). Feasibility was assessed by examining accrual, adherence, and retention rates. Participants completed assessments of exercise capacity (VO2 peak and 6-min walk distance (6MWD)), objective and self-reported levels of physical activity, MRI-derived cardiovascular functioning (Left Ventricular Ejection Fraction [LVEF], stroke volume, and cardiac output), and self-reported health-related and disease-specific quality of life and self-efficacy for exercise at baseline, 3, and 6 months. One hundred and forty-five individuals were screened with 23 of 84 eligible patients agreeing to participate (27%). Three participants withdrew before baseline testing. Out of the 20 participants randomized to the PAI (n = 13) and HLI groups (n = 7), 18 completed the intervention resulting in an overall retention rate of 78%. The adherence rates to the PAI and HLI were 85% and 87%, respectively. One non-serious adverse event was registered. VO2 peak ranged from 15.5–28.0 ml/kg/min at baseline and participants in both groups improved by 6 months. Physical activity levels and cardiovascular function were reduced prior to treatment but did not deteriorate further. Implementing a tailored PAI in adults with lymphoma during active treatment is feasible, was well received by participants and shows preliminary efficacy for limiting a decline in function during treatment. Potential Implications for Cancer Survivors: Physical activity may be beneficial for improving exercise capacity and health-related quality of life in patients undergoing chemotherapy. #NCT01719562 ClinicalTrials.gov. Registered July 2, 2019—retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2025) conducted an RCT in Lymphoma (non-Hodgkin or Hodgkin) undergoing treatment (n=20). Physical activity intervention (PAI) vs. Healthy living intervention (HLI) was evaluated on Feasibility (adherence rate). A 6-month tailored physical activity intervention in adults with lymphoma undergoing treatment was feasible, demonstrating a 27% accrual rate, 78% retention rate, and 85% adherence with minimal adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: